“…54 It has been reported that some drugs or natural products with hypoglycemic activity are able to improve dyslipidemia caused by diabetes by regulating the expression of genes related to fatty acid synthesis and lipid metabolism. 46,48 Therefore, the expression of the key transcription factor of lipid metabolism (SREBP-1c), downstream adipogenic genes (including FAS and ACC), and nuclear receptors (PPARα and PPARγ) of regulating fatty acid oxidation were used to evaluate the effects of LBFs on the diabetes mice. The results showed that LBFs intervention could significantly reduce the gene expression of PPARγ, FAS, ACC, and SREBP-1c, which is related to fat synthesis and accumulation, and remarkably enhances the expression of PPARα, which promoted fatty-acid oxidation.…”